Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analyst here at J.P. Morgan. I'm joined by my squad, Rati Pinge, Priyanka Grover, and Joyce Zhou. Yes, I almost called her JZ. That's what I normally do. Our next presenting company is Neurocrine. And presenting on behalf of the company, we have Kyle Gano, CEO.
Thanks, Anupam, and thanks to the J.P. Morgan Squad and J.P. Morgan for having Neurocrine here at be on the first day. It really is a great way to kick off the week and year for the company. So maybe just to kick things off here, some housekeeping. I will be making forward-looking statements. I'd like to direct you all to our latest SEC filings for the risk factors of the business.
With that behind us, then, I really would like to ground everyone here on two overarching themes that are important for Neurocrine for 2026. One here, as you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
